David Gerber, M.D. - Faculty Profile

Biography

David Gerber, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of the Division of Hematology and Oncology. He serves as Co-Director of the Experimental Therapeutics Program.

Originally from Chicago, Dr. Gerber holds a bachelor's degree in history from Yale University in New Haven, Connecticut, where he graduated cum laude. He earned his medical degree at Cornell University Medical College in New York and completed his internship and residency in internal medicine at UT Southwestern, where he served as Chief Resident. He then received advanced training through a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore.

Certified by the American Board of Internal Medicine in medical oncology, Dr. Gerber joined the UT Southwestern faculty in 2007. He is invested in helping patients have a better quality of life.

Dr. Gerber is active in research related to lung cancer, including clinical trials. His research has generated more than 250 publications that he has authored or co-authored, including articles and book chapters. His studies have contributed to invitations to lecture both nationally and internationally.

He serves on several committees at UT Southwestern. Beyond the institution, he serves as Chair of the Clinical Trials Advisory Committee for the Cancer Prevention and Research Institute of Texas (CPRIT) and is a member of the National Comprehensive Cancer Network (NCCN) Oncology Research Program Investigator Steering Committee.

Dr. Gerber holds memberships in several professional organizations, and he has been honored with numerous awards, including being named a Best Doctor in Dallas by D Magazine during the years of 2011-2023.

Education

Medical School: Weill Cornell Graduate School of Medical Science (2000)
Residency: UT Southwestern Medical Center (2004), Internal Medicine
Fellowship: Johns Hopkins Hospital (2007), Medical Oncology

Research Interest

Lung Cancer, Clinical and Translational Research
Oncology Outcomes

Publications

Concerning safety and efficacy of concurrent and consolidative durvalumab with thoracic radiotherapy in PDL1-unselected stage III non-small cell lung cancer: brief report: Zhang Y, Iyengar P, Montalvo SK, Westover KD, Rashdan S, Donthireddy KR, Kim J, Dowell JE, Drapkin BJ, Bhalla S, Chukwuma C, Nadeem U, Ahn C, Timmerman R, Gerber DE International Journal of Radiation Oncology Biology Physics 2024 Aug S0360-3016 03177-8
Acknowledging and addressing real-world challenges to treating immune-related adverse events: von Itzstein MS, Gerber DE, Bermas BL, Meara A Journal for ImmunoTherapy of Cancer 2024 Jul 12
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer: Mack PC, Hsu CY, Rodilla AM, Gomez JE, Cagan J, Huang Y, Tavolacci S, Valanparambil RM, Rohs N, Brody R, Nichols B, Carreño JM, Bhalla S, Rolfo C, Gerber DE, Moore A, King JC, Ahmed R, Minna JD, Bunn PA, García-Sastre A, Krammer F, Hirsch FR, Shyr Y Vaccines 2024 Jul 12
Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population: Yi S, Rathod RA, Natchimuthu VS, Bhalla S, Lee JL, Browning T, Adesina JO, Do M, Balis D, Wiliams JG, Kitchell E, Santini NO, Johnson DH, Hamann HA, Craddock Lee SJ, Hughes AE, Gerber DE JNCCN Journal of the National Comprehensive Cancer Network 2024 Jul 22 308-314
Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program: Nwachukwu C, Makhnoon S, Person M, Muthukrishnan M, Kazmi S, Anderson LD, Kaur G, Kapinos KA, Williams EL, Fatunde O, Sadeghi N, Robles F, Basey A, Hulsey T, Pruitt SL, Gerber DE Contemporary Clinical Trials Communications 2024 Jun 39
Use of artificial intelligence chatbots in clinical management of immune-related adverse events: Burnette H, Pabani A, Von Itzstein MS, Switzer B, Fan R, Ye F, Puzanov I, Naidoo J, Ascierto PA, Gerber DE, Ernstoff MS, Johnson DB Journal for ImmunoTherapy of Cancer 2024 May 12
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity: von Itzstein MS, Gerber DE Clinical chemistry 2024 Apr 70 571-573
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations: Bhalla S, Natchimuthu V, Lee JL, Wahid U, Zhu H, Santini NO, Browning T, Hamann HA, Johnson DH, Chiu H, Craddock Lee SJ, Gerber DE JNCCN Journal of the National Comprehensive Cancer Network 2024 Apr 22 151-157
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer: Gerber DE, Wang Y, Ramalingam SS, Bhalla S, Sun Z, Borghaei H, Brahmer JR, Schiller JH Oncologist 2024 Apr 29 342-349
The Joint Problem of Rheumatoid Arthritis and Lung Cancer: Bermas BL, Gerber DE Journal of Thoracic Oncology 2024 Feb 19 196-198

Books

Targeted Therapies for Non-Small Cell Lung Cancer

David E. Gerber (2011). Oxford University Press

Lung Cancer

Apar K. Ganti, David E. Gerber (Ed.) (2014). Oxford University Press

Honors & Awards

National Cancer Institute
(NCI) Director's Award (2023)
Leaders in Clinical Excellence Mentoring Award
UT Southwestern (2022)
Exceptional Research in Navigation Award
Academy of Oncology Nurse & Patient Navigators (2018)
National Cancer Institute (NCI)
Midcareer Investigator Award in Patient-Oriented Research (2016)
Top Doctors
Castle Connolly (2015-2023)
Best Doctors in Dallas
D Magazine (2011-2023)
Clinical Investigator Team Leadership Award
National Cancer Institute (2011)
Career Development Award
American Society of Clinical Oncology (2009)

Professional Associations/Affiliations

American Society of Clinical Oncology
Dallas County Medical Society
Eastern Cooperative Oncology Group
International Association for the Study of Lung Cancer
Texas Medical Association